<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="35212">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01986920</url>
  </required_header>
  <id_info>
    <org_study_id>A-101-SEBK-201</org_study_id>
    <nct_id>NCT01986920</nct_id>
  </id_info>
  <brief_title>Study of Safety, Tolerability and Effectiveness of A-101 in Subjects With Seborrheic Keratosis</brief_title>
  <official_title>A Randomized, Double-Blind, Vehicle-Controlled, Within-Subject, Comparison Study of the Safety, Tolerability, And Effectiveness of A-101 Topical Solution in Subjects With Seborrheic Keratosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aclaris Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aclaris Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the safety, tolerability of A-101 when applied to seborrheic keratosis lesions on
      the back of subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The main objective of this study is to evaluate the safety, effectiveness and tolerability
      of three concentrations of A-101 25%, 32.5%, and 40%, when applied to individual seborrheic
      keratosis target lesions on the back compared with a matching A-101 vehicle.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Actual">March 2014</completion_date>
  <primary_completion_date type="Actual">March 2014</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Physician Lesion Assessment Scale</measure>
    <time_frame>Day 78</time_frame>
    <safety_issue>No</safety_issue>
    <description>Physician's subjective assessment of the condition of the lesion</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject's Self Assessment Scale</measure>
    <time_frame>Day 78</time_frame>
    <safety_issue>No</safety_issue>
    <description>Subjects assessment of the condition of their lesions</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Seborrheic Keratosis</condition>
  <arm_group>
    <arm_group_label>A-101 25%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A-101 32.5%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Mid Dose Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A-101 40%</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High Dose Group</description>
  </arm_group>
  <arm_group>
    <arm_group_label>A-101 Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo group</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A-101 25%</intervention_name>
    <description>Low Dose Concentration of A-101</description>
    <arm_group_label>A-101 25%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A-101 32.5%</intervention_name>
    <description>Mid Dose Concentration of A-101</description>
    <arm_group_label>A-101 32.5%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A-101 40%</intervention_name>
    <description>High Dose Concentration A-101</description>
    <arm_group_label>A-101 40%</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>A-101 Vehicle</intervention_name>
    <description>Placebo</description>
    <arm_group_label>A-101 Vehicle</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Is at least 18 years of age

          2. Has a clinical diagnosis of stable clinically typical seborrheic keratosis

          3. Has at least 4 appropriate seborrheic keratosis target lesions on the back

          4. If subject is a women of childbearing potential, she must have a negative urine
             pregnancy test and must agree to use an active form of birth control for the duration
             of the study

          5. Is non-pregnant and non-lactating

          6. Is in good general health and free of any disease state or physical condition which,
             in the investigator's opinion, might impair evaluation of any target lesion or which
             exposes the subject to an unacceptable risk by study participation

          7. Is willing and able to follow all study instructions and to attend all study visits

          8. Is able to comprehend and willing to sign an Informed Consent Form (ICF).

        Exclusion Criteria:

          1. Has clinically atypical and/or rapidly growing seborrheic keratosis lesions

          2. Has presence of multiple eruptive seborrheic keratosis lesions (Sign of
             Lesser-Trelat)â€ƒ

          3. Has used any of the following systemic therapies within the specified period prior to
             Visit 1:

               -  Retinoids; 180 days

               -  Glucocortico-steroids; 28 days

               -  Anti-metabolites (e.g., methotrexate); 28 days

          4. Has used any of the following topical therapies on the treatment area within the
             specified period prior to Visit 1:

               -  Retinoids; 90 days

               -  Liquid nitrogen, electrodessication, curettage, imiquimod, 5-flurouracil, or
                  ingenol mebutate; 60 days

               -  Glucocortico-steroids or antibiotics; 14 days

               -  Moisturizers/emollients, sunscreens; 12 hours

          5. Has had any LASER, light (e.g., intense pulsed light [IPL], photo-dynamic therapy
             [PDT]) or other energy based therapy on the treatment area within 180 days prior to
             Visit 1

          6. Has a history of keloid formation or hypertrophic scarring

          7. Has a current systemic malignancy

          8. Has a history of, within the 180 days prior to Visit 1, or has a current cutaneous
             malignancy  on the treatment area

          9. Has a current pre-malignancy (e.g., actinic keratosis) on the treatment area

         10. Has had body art (e.g., tattoos, piercing, sculpting, etc.) or any other invasive,
             non-therapeutic procedure performed on the treatment area that, in the opinion of the
             investigator, might put the subject at undue risk or interfere with the study conduct
             or evaluations

         11. Has excessive tan on the treatment area that, in the opinion of the investigator,
             might put the subject at undue risk or interfere with the study conduct or
             evaluations

         12. Has experienced a sunburn on the treatment area within the previous 4 weeks

         13. Has a history of sensitivity to any of the ingredients in the study medications

         14. Has any current skin disease (e.g., psoriasis, atopic dermatitis,  eczema, sun
             damage, etc.), or condition (e.g., sunburn, tattoos, excessive hair, open wounds on
             the back) that, in the opinion of the investigator, might put the subject at undue
             risk or interfere with the study conduct or evaluations

         15. Has participated in an investigational drug trial in which administration of an
             investigational study medication occurred within 30 days prior to Visit 1.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Janet Dubois, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dermresearch, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>DermResearch, Inc.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.aclaristx.com</url>
    <description>Study Sponsor Website</description>
  </link>
  <verification_date>March 2014</verification_date>
  <lastchanged_date>March 10, 2014</lastchanged_date>
  <firstreceived_date>November 6, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>SK</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Keratosis</mesh_term>
    <mesh_term>Keratosis, Actinic</mesh_term>
    <mesh_term>Keratosis, Seborrheic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
